Preoperative Systemic Chemotherapy Including Immune Checkpoint Inhibitors for Patients with Tumor-Associated Dermatomyositis.

ABSTRACT:

Introduction

Immune checkpoint inhibitors (ICIs), used in cancer immunotherapy, enhance the immune system's ability to attack cancer cells. However, this activation can lead to severe immune-associated adverse events due to overactivation. In autoimmune diseases, the immune system mistakenly targets the body's tissues, producing autoantibodies that cause inflammation and tissue damage. Despite the increasing use of ICIs, limited information exists on their effects and potential harms in patients with active autoimmune diseases, making it challenging to predict outcomes and manage risks for these patients.

Case presentation

We report a case of a patient with breast cancer presenting with a rash and muscle weakness. The simultaneous onset of these symptoms, along with the rapi

SUBMITTER: Kawamura Y 

PROVIDER: S-EPMC11825135 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature